ForteBio, Inc. offers the Octet RED System, for label-free, real-time kinetic analysis of drug compounds. The new system brings unparalleled ease-of-use, sensitivity, throughput and affordability to the analysis of small molecules, peptides and proteins for research, development and bioprocessing, according to the company.
The degree to which a drug compound binds to a therapeutic target helps predict a drug candidate’s potency and effectiveness, and is a significant component of drug discovery and lead optimization. A label-free method of analysis avoids label interference with the binding activities of the therapeutic target.
The Octet RED System is based on ForteBio’s proprietary BioLayer Interferometry (BLI) technology, in which optical biosensors measure multiple interactions in parallel, without the use of chemical labeling. The Octet RED System’s high sensitivity and rapid data acquisition capabilities enable analysis of low molecular weight molecules that exhibit fast kinetics, which is critical for comprehensive kinetic characterization of drug candidates.
Filed Under: Drug Discovery